Predictive Technology Group (Predictive Technology Group) Long-Term Capital Lease Obligation : $0.35 Mil (As of Mar. 2021)

View and export this data going back to 2007. Start your Free Trial

What is Predictive Technology Group Long-Term Capital Lease Obligation?

Predictive Technology Group's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2021 was $0.35 Mil.

Predictive Technology Group's quarterly Long-Term Capital Lease Obligation declined from Sep. 2020 ($0.69 Mil) to Dec. 2020 ($0.52 Mil) and declined from Dec. 2020 ($0.52 Mil) to Mar. 2021 ($0.35 Mil).

Predictive Technology Group's annual Long-Term Capital Lease Obligation increased from Jun. 2018 ($0.00 Mil) to Jun. 2019 ($1.51 Mil) but then declined from Jun. 2019 ($1.51 Mil) to Jun. 2020 ($1.11 Mil).

Predictive Technology Group Long-Term Capital Lease Obligation Historical Data

The historical data trend for Predictive Technology Group's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Technology Group Long-Term Capital Lease Obligation Chart

Predictive Technology Group Annual Data

Trend

Aug06

Aug07

Jun16

Jun17

Jun18

Jun19

Jun20

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

1.51

1.11

Predictive Technology Group Quarterly Data
	Nov07	Feb08	May08	Jun16	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															1.51	1.11	0.69	0.52	0.35

Predictive Technology Group (OTCPK:PRED) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Predictive Technology Group Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Predictive Technology Group's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Predictive Technology Group (Predictive Technology Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Predictive Technology Group Inc (OTCPK:PRED) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

2735 Parleys Way, Suite 205, Salt Lake City, UT, USA, 84109

Website

https://www.predtechgroup.com

Predictive Technology Group Inc (PRx) is a biotechnology company. It develops, commercializes, acquires and invests in technologies engaged in novel molecular diagnostic and therapeutic products in healthcare. The HCT/P segment offers minimally manipulated tissue products intended for homologous use, prepared utilizing proprietary extraction methods that reduce the loss of important scaffolding, growth factors and cytokines. The company's Diagnostics and Therapeutics segment uses data analytics for disease identification and subsequent therapeutic intervention through novel gene-based diagnostics, and companion therapeutics. It generates most of its revenues from HCT/Ps segment.